These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26845108)

  • 1. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
    Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
    Adams A; Scheckel B; Habsaoui A; Haque M; Kuhr K; Monsef I; Bohlius J; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD012633. PubMed ID: 35724934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early erythropoiesis-stimulating agents in preterm or low birth weight infants.
    Ohlsson A; Aher SM
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004863. PubMed ID: 29145693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early erythropoiesis-stimulating agents in preterm or low birth weight infants.
    Ohlsson A; Aher SM
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD004863. PubMed ID: 32048730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
    Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
    O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.
    Kaufner L; von Heymann C; Henkelmann A; Pace NL; Weibel S; Kranke P; Meerpohl JJ; Gill R
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012451. PubMed ID: 32790892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
    Aher SM; Ohlsson A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD004868. PubMed ID: 30776084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.
    Aher SM; Ohlsson A
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD004868. PubMed ID: 31990982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
    Estcourt LJ; Malouf R; Trivella M; Fergusson DA; Hopewell S; Murphy MF
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011305. PubMed ID: 28128441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
    Radford M; Estcourt LJ; Sirotich E; Pitre T; Britto J; Watson M; Brunskill SJ; Fergusson DA; Dorée C; Arnold DM
    Cochrane Database Syst Rev; 2024 May; 5(5):CD011305. PubMed ID: 38780066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harms of off-label erythropoiesis-stimulating agents for critically ill people.
    Mesgarpour B; Heidinger BH; Roth D; Schmitz S; Walsh CD; Herkner H
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010969. PubMed ID: 28841235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin or darbepoetin for patients with cancer.
    Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
    Hahn D; Cody JD; Hodson EM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.